Shilpa Medicare’s wholly owned subsidiary - Koanna Healthcare, UK, has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for the IMATINIB TABLETS in multiple strengths of 100 mg and 400 mg.
The marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc. Out of 15 member states the first approval is received from UKMHRA. Approvals from remaining member states will follow.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: